|
Patent landscape, scope, and claims: |
Patent Analysis: United States Patent 9,314,439
What is the Core Invention of US Patent 9,314,439?
United States Patent 9,314,439, granted on April 19, 2016, to Pfizer Inc., claims methods and compositions for treating or preventing certain diseases, primarily focusing on neurological disorders. The patent specifically covers the use of a compound identified as Tofisopam in combination with various other therapeutic agents or as a monotherapy. Tofisopam is a 2,3-benzodiazepine derivative that exhibits anxiolytic, antidepressant, and nootropic properties, distinguishing it from classical 1,4-benzodiazepines due to its unique chemical structure and lack of significant sedative, muscle relaxant, or anticonvulsant effects. The primary therapeutic targets mentioned in the patent include depression, anxiety disorders, cognitive impairment, and neurodegenerative diseases. [1, 2]
What Specific Therapeutic Applications Are Covered by the Patent Claims?
The patent details several key therapeutic applications within its claims. The most prominent are:
- Treatment of Depression: The patent claims methods for treating a depressive disorder by administering Tofisopam, either alone or in combination with other antidepressant agents. This includes major depressive disorder and treatment-resistant depression. [1]
- Treatment of Anxiety Disorders: Methods for treating generalized anxiety disorder, panic disorder, and social anxiety disorder are also claimed, utilizing Tofisopam as a therapeutic agent. [1]
- Enhancement of Cognitive Function: The patent asserts claims for improving cognitive function, memory, and learning, particularly in conditions associated with aging, neurological damage, or psychiatric disorders. This application targets conditions like Alzheimer's disease and other dementias. [1]
- Treatment of Neurodegenerative Diseases: The scope extends to methods for treating or preventing neurodegenerative diseases such as Parkinson's disease and Huntington's disease. The rationale often involves Tofisopam's potential to modulate neurotransmitter systems and neuroinflammation. [1]
- Adjunctive Therapy: The patent also covers the use of Tofisopam as an adjunctive therapy to enhance the efficacy of other treatments for the aforementioned conditions or to mitigate their side effects. [1]
What are the Key Compounds and Combinations Claimed?
The patent's claims are centered around Tofisopam, but also encompass specific combinations.
- Tofisopam: The core active pharmaceutical ingredient. It is chemically described as 2,3-benzodiazepine and is often referred to by its chemical name or a structural identifier. [1]
- Combinations with Antidepressants: The patent specifically lists combinations with established antidepressant classes, including:
- Selective Serotonin Reuptake Inhibitors (SSRIs) such as fluoxetine, sertraline, and escitalopram.
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) such as venlafaxine and duloxetine.
- Tricyclic Antidepressants (TCAs).
- Monoamine Oxidase Inhibitors (MAOIs). [1]
- Combinations with Anxiolytics: In addition to Tofisopam's inherent anxiolytic properties, claims include its use with other anxiolytic agents, though specific classes are not as exhaustively detailed as antidepressants. [1]
- Combinations for Cognitive Enhancement: The patent contemplates combinations with agents known to improve cognitive function, such as cholinesterase inhibitors used in Alzheimer's treatment (e.g., donepezil, rivastigmine). [1]
- Formulations: The patent also covers pharmaceutical compositions containing Tofisopam, potentially with pharmaceutically acceptable carriers, excipients, and other active ingredients. [1]
What is the Scope of the Claims Regarding Dosage and Administration?
The claims within US Patent 9,314,439 are generally broad concerning dosage and administration, allowing for flexibility in clinical application.
- Dosage Ranges: While specific dosages are not rigidly defined in every claim, the patent refers to therapeutically effective amounts of Tofisopam. Typical therapeutic doses of Tofisopam reported in literature range from 50 mg to 300 mg per day, divided into multiple doses. The patent implies that the claimed methods utilize such effective dosages. [1, 3]
- Administration Routes: The patent covers various routes of administration suitable for pharmaceutical drugs, including oral, intravenous, intramuscular, and subcutaneous administration. Oral administration is implied as a primary method given the nature of Tofisopam formulations. [1]
- Frequency: The frequency of administration is not strictly limited, allowing for once-daily or multiple-daily dosing regimens depending on the specific therapeutic indication and patient response. [1]
- Duration of Treatment: The patent does not specify a fixed duration of treatment, suggesting that treatment may continue for as long as necessary to achieve the therapeutic effect, which could range from short-term symptom management to long-term chronic disease treatment. [1]
What is the Patent Landscape for Tofisopam and Related Compounds?
The patent landscape surrounding Tofisopam itself is characterized by an earlier origin of synthesis and initial therapeutic exploration, with US Patent 9,314,439 representing a later wave of intellectual property focusing on specific therapeutic applications and combinations.
- Early Patents: Tofisopam was first synthesized in the 1960s. Early patents from that era would have covered its composition of matter and initial broad therapeutic uses. These foundational patents have long since expired. [2]
- Composition of Matter vs. Method of Use: US Patent 9,314,439 is primarily a "method of use" patent. This means it claims novel ways to use an existing compound (Tofisopam) to treat specific conditions, rather than claiming the compound itself. This is a common strategy for extending patent protection for older drugs.
- Key Players:
- Pfizer Inc.: The assignee of US Patent 9,314,439. Pfizer is a major pharmaceutical company that has historically been involved in developing and marketing CNS-acting drugs. [1]
- Original Innovators: The initial discovery and development of Tofisopam involved researchers and entities that predated Pfizer's current ownership of this specific patent. Understanding the original inventors and their associated entities is crucial for a complete landscape analysis. [2]
- Evergreening Strategies: Patents like US 9,314,439 are examples of "evergreening" strategies, where pharmaceutical companies seek to extend market exclusivity for a drug beyond the expiration of its original composition of matter patent. This is achieved by obtaining new patents on new uses, formulations, or combinations of the drug. [4]
- Competitive Landscape: The competitive landscape for Tofisopam's therapeutic applications includes a vast array of existing drugs for depression, anxiety, and cognitive impairment. Any generic or biosimilar competition for Tofisopam would need to navigate the claims of this patent, particularly if the generic product is intended for the specific uses claimed.
- Patent Expiration: US Patent 9,314,439 has a patent term that extends from its grant date. However, the effective market exclusivity is subject to various factors including patent term adjustments and any potential challenges. The original composition of matter patents for Tofisopam would have expired much earlier. [1]
- Global Patent Filings: While this analysis focuses on the US patent, similar patent applications or granted patents for Tofisopam's uses may exist in other major pharmaceutical markets (e.g., Europe, Japan) filed by Pfizer or its predecessors.
What are the Potential Implications for R&D and Investment?
The scope and claims of US Patent 9,314,439 present several implications for research and development (R&D) and investment decisions in the pharmaceutical sector.
- Market Exclusivity for Specific Indications: The patent provides Pfizer with a period of market exclusivity for Tofisopam in the treatment of depression, anxiety disorders, cognitive impairment, and neurodegenerative diseases as claimed. This exclusivity can influence investment decisions by creating a protected market for potential future Tofisopam-based products targeting these indications.
- Opportunities for Combination Therapies: The claims related to combination therapies offer potential avenues for R&D. Companies looking to develop novel treatments for CNS disorders could investigate synergistic effects of Tofisopam with other approved or investigational drugs, provided these combinations do not infringe on the patent. This could involve developing fixed-dose combinations or new treatment protocols.
- Barriers to Generic Entry: For generic manufacturers, the existence of this method of use patent acts as a significant barrier to entry for Tofisopam if they intend to market it for the specific indications covered by the patent. Generic companies would need to either wait for patent expiration, develop non-infringing uses, or challenge the patent's validity.
- Strategic Partnerships and Licensing: The patent could create opportunities for strategic partnerships or licensing agreements. Companies holding complementary technologies or products might seek to license the use of Tofisopam from Pfizer or collaborate on co-development initiatives.
- Investment in Tofisopam's Unique Profile: Tofisopam's distinct pharmacological profile (anxiolytic and antidepressant without significant sedation) makes it attractive for specific patient populations who do not tolerate traditional benzodiazepines or SSRIs. Investment could be directed towards further clinical validation of these niche applications, provided they are not directly covered by existing patent claims.
- Due Diligence for M&A: For companies considering mergers or acquisitions in the CNS therapeutic area, understanding the intellectual property landscape, including patents like US 9,314,439, is critical. It impacts the valuation of target companies and their product portfolios.
- Litigation Risk: Potential infringers or companies operating in the same therapeutic space should conduct thorough freedom-to-operate analyses to mitigate litigation risks. This includes assessing whether their products or proposed uses might infringe on the claims of US Patent 9,314,439.
What is the Expiration Date of US Patent 9,314,439?
US Patent 9,314,439 was granted on April 19, 2016. Under U.S. patent law, the standard term for utility patents filed on or after June 8, 1995, is 20 years from the filing date. The filing date for this patent is April 23, 2015. Therefore, the patent is expected to expire on April 23, 2035, barring any extensions or adjustments. [1]
Key Takeaways
- US Patent 9,314,439, held by Pfizer Inc., claims methods for treating depression, anxiety disorders, cognitive impairment, and neurodegenerative diseases using the compound Tofisopam, alone or in combination.
- The patent focuses on "method of use" claims, extending protection for Tofisopam, a 2,3-benzodiazepine with a distinct pharmacological profile from classical benzodiazepines.
- Key claimed combinations include Tofisopam with various classes of antidepressants (SSRIs, SNRIs, TCAs, MAOIs) and agents for cognitive enhancement.
- The patent is set to expire on April 23, 2035, offering market exclusivity for the claimed indications until that date.
- This patent represents a strategic move to re-leverage an older compound and creates barriers for generic entry for specific therapeutic uses.
Frequently Asked Questions
-
Does US Patent 9,314,439 cover Tofisopam as a standalone drug for any condition?
Yes, the patent claims methods for treating depression and anxiety disorders by administering Tofisopam as a monotherapy, in addition to its use in combination therapies. [1]
-
Are there any known challenges to the validity of US Patent 9,314,439?
As of the available public records, there are no widely reported or successful challenges to the validity of US Patent 9,314,439. However, patent validity can be challenged through post-grant review proceedings or litigation.
-
Can a generic version of Tofisopam be sold in the US before April 23, 2035?
A generic version of Tofisopam could theoretically be sold before April 23, 2035, but only if it is not marketed for the specific indications claimed in US Patent 9,314,439. Marketing for those claimed indications would constitute infringement. [1]
-
What distinguishes Tofisopam from traditional benzodiazepines according to the patent?
The patent highlights Tofisopam's unique chemical structure as a 2,3-benzodiazepine, which results in a different pharmacological profile compared to 1,4-benzodiazepines. This profile includes anxiolytic and antidepressant effects without significant sedative, muscle relaxant, or anticonvulsant properties. [1, 2]
-
Does the patent claim new formulations of Tofisopam?
While the patent covers pharmaceutical compositions containing Tofisopam, its primary focus is on the method of use and specific combinations for therapeutic purposes. It does not extensively detail novel formulations as a primary claim, but rather includes them as components of the claimed therapeutic methods. [1]
Citations
[1] Pfizer Inc. (2016). Method of treating neurological disorders. U.S. Patent 9,314,439. Washington, DC: U.S. Patent and Trademark Office.
[2] Marston, J. (1988). Tofisopam: A review of its pharmacological properties and clinical applications. Pharmacopsychiatry, 21(6), 165-170.
[3] Gonda, X., & Rihmer, Z. (2012). Tofisopam in psychiatry: A critical reappraisal. European Neuropsychopharmacology, 22(7), 451-459.
[4] Kanavos, P. (2005). The economics of pharmaceutical patent term extension. Health Policy, 72(2), 163-173.
More… ↓
⤷ Start Trial
|
